metaEvidence - overview


			DCR
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive
mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population
versus BSC
	avelumab alone vs. BSC	1	1.85 [1.35; 2.54], 1 RCT, I2=0% unassessable degree of certainty
mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive
versus BSC
	avelumab alone vs. BSC	1	2.03 [1.31; 3.16], 1 RCT, I2=0% unassessable degree of certainty
MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population
MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive